secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001628280-22-020207
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis gets FDA approval for ZORYVE (roflumilast) cream 0.3% for plaque psoriasis; draws $125M in debt
--------------------------------------------------------------------------------

- FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis, including intertriginous areas, in patients 12+.
- First and only topical PDE4 inhibitor approved for plaque psoriasis; once-daily, steroid-free, no duration limit.
- Commencing $125M drawdown of Tranche B term loans from SLR Investment Corp. to fund launch and pipeline.
- Product expected to be available via wholesalers and dermatology pharmacies by mid-August 2022.
- DERMIS-1/2 Phase 3 trials: 42% and 37% IGA success at Week 8 (P<0.0001); itch reduction as early as Week 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022020207/0001628280-22-020207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022020207/arqt-20220729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-020207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer